CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03782415
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:47.082087+00:00
Published At: 2025-05-21T00:00:00+00:00
Record Updated At: 2025-05-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Glioblastoma", "Recurrent Glioblastoma", "GBM", "Newly Diagnosed Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-21"
protocolSection.identificationModule.nctId: "NCT03782415"
protocolSection.identificationModule.officialTitle: "Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.